Two elective invasive procedures after a single avatrombopag treatment in a patient with liver cirrhosis and severe thrombocytopenia  

作　　者：Marco Biolato Federica Vitale Giuseppe Marrone Luca Miele Antonio Grieco 

机构地区：[1]Internal and Liver Transplant Medicine Unit,CEMAD,Department of Medical and Surgical Sciences,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Rome,Italy [2]Institute of Internal Medicine,Catholic University of the Sacred Heart,Rome,Italy

出　　处：《Gastroenterology Report》2022年第1期668-670,共3页胃肠病学报道（英文）

摘　　要：Introduction Severe thrombocytopenia(platelet count<50×10^(9)/L)occurs in 1%–2%of patients with liver cirrhosis and is associated with an increased risk of bleeding[1].In this clinical setting,there is no definite agreement on the platelet cut-off below which bleeding risk increases.However,in vitro evidence indicates that thrombin generation is preserved in patients with cirrhosis and platelet counts of>56×10^(9)/L[2].Observational studies found that severe thrombocytopenia may be predictive of post-procedure bleeding after liver biopsy,dental extractions,percutaneous ablation of liver tumors,and endoscopic polypectomy[3].

关 键 词：TREATMENT CIRRHOSIS LIVER 

分 类 号：R575.5[医药卫生—消化系统] R574[医药卫生—内科学]